Biotech Mailbag: All About Alnylam By Adam Feuerstein About this article: Pass the stuffing and please, more cranberry sauce! The Thanksgiving Biotech Mailbag is open for business. Robert C. writes: "What is your opinion and record of following Alnylam Pharmaceuticals? I am a physician with a research background and although I know that major pitfalls exist of function and approval I cannot see why there is not more interest in this potentially life-changing therapy." Take your eyes off Alnylam's stock chart for a moment and glance at the company's balance sheet, which will be laden with more than $500 million when the year comes to a close. That's a very nice cash cushion to have these days. Biotech firms are running out of money right and left, and the equity and debt markets are clamped tight, so for Alnylam to be sitting on several years of cash without any need for additional financing is a good thing indeed. Kudos to... Or, call us at 1-866-321-TSCM (8726) Monday-Friday, 8 a.m.-6 p.m. ET. Outside the U.S. and in Canada, call 1-212-321-5200. More Stories From RealMoney Durable Goods Up Move Down the Tech Food Chain Jobless Claims Still High Bulls' Tenacity Is the Big Question Mark Should You Buy It? Pharmaceutical Product Development Bad News Trumps All Support for Banks Holds, For Now Bummer, Yields Are on the Rise Money on the Line Makes a Big Difference Structured Products: Unsafe at Any Price MORE STORIES FROM REALMONEY

If you choose a 14-day free trial of RealMoney and you do NOT call to cancel within those 14 days, you will pay $129.95 — a $100 savings off the regular annual subscription price of $229.95. Unless you cancel before the end of that year, your subscription will automatically renew for another year at the then-current subscription price.

Offer applies only to new annual subscriptions, and is subject to change at any time. Void where prohibited.

If you choose a monthly subscription, you pay $34.95 per month. You will be notified if the current monthly rate of $34.95 changes at any time in the future.

TheStreet.com is a publisher. None of the contributors or their affiliates will provide you with personally tailored advice concerning the nature, potential, value or suitability of any particular security, portfolio of securities, transaction, investment strategy or other matter. From time to time, any or all of the contributors or their affiliates may hold positions in securities mentioned and they may trade for their own accounts. In cases where the position is held at the time of publication, appropriate disclosure is made.

© TheStreet.com, Inc., 14 Wall Street, 15th Floor, New York, NY 10005.